Tonix Pharmaceuticals' TNX-1500, an anti-CD40L monoclonal antibody, demonstrated favorable safety and tolerability in Phase I trial with 26 healthy subjects across three dose cohorts.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.